Brett Scott CFO Copyright Business Wire 2009

They include Prospera brachytherapy seeds andSurTRAK needles and strands used primarily in the treatment of prostate cancer.In addition, the Company has continued to gain clinical experience with itsClearPath multi-channel catheter breast brachytherapy devices. They are the onlysuch devices approved for both high dose and continuous release, or low dose,radiation treatments. The devices are designed to provide flexible, precise doseconformance and an innovative delivery system that is intended to offer the moreadvanced form of brachytherapy for the treatment of breast cancer Please visit for more information. Statements included in this release that are not historical facts may beconsidered forward-looking statements that are subject to a variety of risks anduncertainties. There are a number of important factors that could cause actualresults to differ materially from those expressed in any forward-lookingstatements made by the Company including, but not limited to, the impact ofcompetitive products and pricing, technological changes, changes inrelationships with strategic partners and dependence upon strategic partners forthe performance of critical activities under collaborative agreements, theability of the Company to successfully directly market and sell its products,uncertainties relating to patent protection and regulatory approval, the stablesupply of appropriate isotopes, research and development estimates, marketopportunities, risks associated with strategic opportunities or acquisitions theCompany may pursue and the risk factors included in the Companys filings withthe Securities and Exchange Commission. Any forward-looking statements containedin this news release speak only as of the date of this release, and the Companyundertakes no obligation to revise or update any forward-looking statements,whether as a result of new information, future results or otherwise.North American Scientific, Inc.Brett Scott, CFO, Copyright Business Wire 2009. Reconfirms Full Year 2008 Financial Guidance; Schedules Investor Conference CallCONSHOHOCKEN, Pa.(Business Wire)CardioNet, Inc.

(NASDAQ:BEAT), a leading wireless medical technology companywith an initial focus on the diagnosis and monitoring of cardiac arrhythmias,announced today that the Board of Directors has appointed Randy Thurman,currently the Boards Executive Chairman, as Interim President and ChiefExecutive Officer, effective immediately. The Board also announced that it hascommenced a search for a permanent replacement for departing President and ChiefExecutive Officer, Arie Cohen, who has left the company to pursue otherinterests Mr. Thurman most recently served as Chairman and CEO of VIASYS Healthcare Inc.,a global medical technology company that was acquired by Cardinal Health in June2007 for $1.5 billion From VIASYS successful IPO in 2001 to 2007, Mr. Thurmanspearheaded an aggressive growth strategy that increased the Companys revenuesfrom $320 million to $700 million and positioned the Company to consummatetwelve strategic acquisitions over a six-year period.

His leadership alsoenabled VIASYS to expand its enterprise value more than fourfold during thattime. In 2007, VIASYS was named by Smart Money as one of the "Ten Stocks for theNext Ten Years." Prior to VIASYS, Mr. Thurman was Chairman of the Board and CEO of Corning LifeSciences, a diversified medical technology company with a focus in contractpharmaceutical research, contract biologic manufacturing and clinical diagnostictesting Earlier in his career, Mr. Thurman was President of Rhone-Poulenc RorerPharmaceuticals Inc., a global, research-based pharmaceutical company. Mr.Thurman was named by Ernst and Young as Entrepreneur of the Year in healthcaretechnology in 2007. He is currently Senior Advisor to New Mountain Capital, LLC,a leading private and public equity investment firm Mr.